Madrigal Pharmaceuticals Stock Beta
| MDGL Stock | USD 194.38 10.27 5.02% |
Madrigal Pharmaceuticals fundamentals help investors to digest information that contributes to Madrigal Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Madrigal Stock. The fundamental analysis module provides a way to measure Madrigal Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Madrigal Pharmaceuticals stock.
Madrigal | Beta |
Madrigal Pharmaceuticals Company Beta Analysis
Madrigal Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Madrigal Pharmaceuticals Beta | -0.44 |
Most of Madrigal Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Madrigal Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Madrigal Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Madrigal Pharmaceuticals is extremely important. It helps to project a fair market value of Madrigal Stock properly, considering its historical fundamentals such as Beta. Since Madrigal Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Madrigal Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Madrigal Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Madrigal Pharmaceuticals has a Beta of -0.437. This is 150.81% lower than that of the Biotechnology sector and 131.44% lower than that of the Health Care industry. The beta for all United States stocks is 191.33% higher than that of the company.
Madrigal Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Madrigal Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Madrigal Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Madrigal Pharmaceuticals by comparing valuation metrics of similar companies.Madrigal Pharmaceuticals is currently under evaluation in beta category among related companies.
Madrigal Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Madrigal Pharmaceuticals from analyzing Madrigal Pharmaceuticals' financial statements. These drivers represent accounts that assess Madrigal Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Madrigal Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.4B | 1.7B | 1.4B | 5.0B | 4.3B | 4.5B | |
| Enterprise Value | 1.4B | 1.7B | 1.4B | 4.7B | 4.3B | 4.6B |
Madrigal Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Madrigal Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Madrigal Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Madrigal Pharmaceuticals' value.| Shares | Geode Capital Management, Llc | 2023-12-31 | 336.3 K | Bain Capital Life Sciences Investors, Llc | 2023-12-31 | 324.6 K | Artisan Partners Limited Partnership | 2023-12-31 | 296.5 K | Citadel Advisors Llc | 2023-09-30 | 276.8 K | Jane Street Group, Llc | 2023-12-31 | 216.8 K | Alpinvest Partners N.v. | 2023-12-31 | 211.5 K | Ra Capital Management, Llc | 2023-12-31 | 204.5 K | Rock Springs Capital Management Lp | 2023-12-31 | 198.2 K | Group One Trading, Lp | 2023-12-31 | 191.9 K | Hhg Plc | 2023-12-31 | 2.9 M | Baker Bros Advisors Lp | 2023-12-31 | 2 M |
As returns on the market increase, returns on owning Madrigal Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Madrigal Pharmaceuticals is likely to outperform the market.
Madrigal Fundamentals
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | 3.56 B | ||||
| Shares Outstanding | 20.97 M | ||||
| Shares Owned By Insiders | 9.24 % | ||||
| Shares Owned By Institutions | 94.86 % | ||||
| Number Of Shares Shorted | 3.41 M | ||||
| Price To Earning | (13.96) X | ||||
| Price To Book | 12.24 X | ||||
| EBITDA | (379.97 M) | ||||
| Net Income | (373.63 M) | ||||
| Cash And Equivalents | 211.77 M | ||||
| Cash Per Share | 12.38 X | ||||
| Total Debt | 117.19 M | ||||
| Debt To Equity | 0.59 % | ||||
| Current Ratio | 2.55 X | ||||
| Book Value Per Share | 20.39 X | ||||
| Cash Flow From Operations | (324.23 M) | ||||
| Short Ratio | 6.17 X | ||||
| Earnings Per Share | (19.99) X | ||||
| Target Price | 377.07 | ||||
| Number Of Employees | 376 | ||||
| Beta | -0.44 | ||||
| Market Capitalization | 4.09 B | ||||
| Total Asset | 640.55 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 518.73 M | ||||
| Current Asset | 363.58 K | ||||
| Current Liabilities | 49.28 M | ||||
| Net Asset | 640.55 M |
About Madrigal Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Madrigal Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Madrigal Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Madrigal Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Madrigal Pharmaceuticals Piotroski F Score and Madrigal Pharmaceuticals Altman Z Score analysis. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.Note that the Madrigal Pharmaceuticals information on this page should be used as a complementary analysis to other Madrigal Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Madrigal Stock analysis
When running Madrigal Pharmaceuticals' price analysis, check to measure Madrigal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Madrigal Pharmaceuticals is operating at the current time. Most of Madrigal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Madrigal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Madrigal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Madrigal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Madrigal Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.99) | Return On Assets (0.47) | Return On Equity (1.24) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.